New Paradigms for CKD Management in Patients With T2D

Joshua J. Neumiller; Stephen A. Brunton

doi:10.12788/jfp.0621

New Paradigms for CKD Management in Patients With T2D

Joshua J. Neumiller
, Stephen A. Brunton

Washington

Research output: Contribution to journal › Article › peer-review

Abstract

LEARNING OBJECTIVES: At the end of the activity, participants will be able to: Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2D). Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2D. Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2D and CKD. Become familiar with the novel nonsteroidal mineralocorticoid receptor antagonist finerenone and its role in the treatment of patients with T2D and CKD.

Original language	English
Pages (from-to)	S37-S42
Journal	Journal of Family Practice
Volume	72
Issue number	6
DOIs	https://doi.org/10.12788/jfp.0621
State	Published - Jul 1 2023

Access to Document

10.12788/jfp.0621

Cite this

@article{2f934bcb808f4ad9816cbcb24d1ea54b,

title = "New Paradigms for CKD Management in Patients With T2D",

abstract = "LEARNING OBJECTIVES: At the end of the activity, participants will be able to: Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2D). Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2D. Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2D and CKD. Become familiar with the novel nonsteroidal mineralocorticoid receptor antagonist finerenone and its role in the treatment of patients with T2D and CKD.",

author = "Neumiller, \{Joshua J.\} and Brunton, \{Stephen A.\}",

year = "2023",

month = jul,

day = "1",

doi = "10.12788/jfp.0621",

language = "English",

volume = "72",

pages = "S37--S42",

journal = "Journal of Family Practice",

issn = "0094-3509",

publisher = "Frontline Medical Communications Inc.",

number = "6",

}

TY - JOUR

T1 - New Paradigms for CKD Management in Patients With T2D

AU - Neumiller, Joshua J.

AU - Brunton, Stephen A.

PY - 2023/7/1

Y1 - 2023/7/1

N2 - LEARNING OBJECTIVES: At the end of the activity, participants will be able to: Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2D). Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2D. Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2D and CKD. Become familiar with the novel nonsteroidal mineralocorticoid receptor antagonist finerenone and its role in the treatment of patients with T2D and CKD.

AB - LEARNING OBJECTIVES: At the end of the activity, participants will be able to: Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2D). Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2D. Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2D and CKD. Become familiar with the novel nonsteroidal mineralocorticoid receptor antagonist finerenone and its role in the treatment of patients with T2D and CKD.

UR - https://www.scopus.com/pages/publications/85166784563

U2 - 10.12788/jfp.0621

DO - 10.12788/jfp.0621

M3 - Article

C2 - 37549415

AN - SCOPUS:85166784563

SN - 0094-3509

VL - 72

SP - S37-S42

JO - Journal of Family Practice

JF - Journal of Family Practice

IS - 6

ER -

New Paradigms for CKD Management in Patients With T2D

Abstract

Access to Document

Other files and links

Fingerprint

Cite this